Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
Dr Robert Coleman reviews data from the ARIEL-4 trial on rucaparib in recurrent ovarian cancer, sparking a discussion on PARP inhibitor use.
Now Viewing
EP: 1.Recent Updates in PARP Inhibitor Indications for Ovarian Cancer
EP: 2.PARP Inhibitors in Ovarian Cancer: The SOLO-3 Trial
EP: 3.PARP Inhibitors as Frontline Maintenance Therapy in Ovarian Cancer
EP: 4.Olaparib Combinations for Frontline Maintenance Therapy in Ovarian Cancer Treatment: The PAOLA-1 Trial
EP: 5.Niraparib Maintenance Therapy in Ovarian Cancer: The PRIMA Trial
EP: 6.The Rationale for PARP Inhibition plus IO in Ovarian Cancer
EP: 7.Novel Maintenance Strategies Being Explored in Advanced Ovarian Cancer Treatment
EP: 8.PARP Inhibitor Resistance in Ovarian Cancer Treatment
EP: 9.The Rationale for PARP Inhibitor Treatment for HRD-Positive Ovarian Cancer
EP: 10.Antibody-Drug Conjugates in Ovarian Cancer Treatment
EP: 11.Clinical Trial Data on Antibody-Drug Conjugate Treatment for Ovarian Cancer
EP: 12.Investigative Therapies in Recurrent Ovarian Cancer
EP: 13.Treatment of Rare Tumors in Ovarian Cancer
EP: 14.Key Data Highlights in Ovarian Cancer
Related Videos
Related Content
